Department of Applied Health Science, School of Public Health, Indiana University, Bloomington, IN, United States.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Pain. 2023 Apr 1;164(4):e228-e236. doi: 10.1097/j.pain.0000000000002790. Epub 2022 Sep 26.
Opioid-involved motor vehicle traffic fatalities have increased over the past 2 decades. However, the extent to which prescribed opioids increase the risk of motor vehicle crashes remains uncertain. This study used real-world healthcare claims data to examine the association between prescription opioid dose and motor vehicle crash risk. Using nationwide US commercial insurance claims data for 2010 to 2018, we identified 772,404 adults who received incident, noncancer opioid therapy. We examined associations between daily prescription opioid dose, calculated in morphine milligram equivalents (MME) from filled prescription claims, and risk of motor vehicle crashes, assessed as diagnoses of motor vehicle injuries in claims for emergency visits, inpatient hospitalizations, and ambulance transportation. We estimated associations using a within-individual design, which ruled out all time-stable confounding. We complemented the design with time-varying statistical adjustment for other pharmacotherapies and a negative control pain pharmacotherapy analysis (with incident cyclic antidepressant prescriptions). During 2,150,009 person-years of follow-up, there were 12,123 motor vehicle crashes (5.64 crashes per 1000 person-years). In within-individual comparisons, crash risk was greater during opioid prescription periods involving doses ≤60 MME/day (odds ratio [OR], 3.86; 95% confidence interval [CI], 3.54, 4.21), >60 to 120 MME/day (OR, 5.46; 95% CI, 4.44, 6.73), and >120 MME/day (OR, 3.45; 95% CI, 2.31, 5.15) than during off-treatment periods. The negative control analysis supported the specificity of the results to opioids rather than to other processes associated with pharmacologic pain management. These findings suggest that the receipt of prescription opioids, even at doses ≤60 MME/day, is associated with an increased risk of motor vehicle crashes.
在过去的 20 年里,涉及阿片类药物的机动车交通死亡人数有所增加。然而,处方阿片类药物增加机动车事故风险的程度仍不确定。本研究使用真实世界的医疗保健索赔数据来研究处方阿片类药物剂量与机动车碰撞风险之间的关系。使用 2010 年至 2018 年美国全国商业保险索赔数据,我们确定了 772404 名接受非癌症阿片类药物治疗的成年人。我们检查了从填充分配索赔中计算得出的每日处方阿片类药物剂量(以吗啡毫克当量表示)与机动车事故风险之间的关联,评估方法为在索赔中出现机动车损伤的诊断紧急就诊、住院和救护车转运。我们使用个体内设计来估计关联,该设计排除了所有时间稳定的混杂因素。我们通过时间变化的统计学调整补充了设计,包括其他药物治疗和阴性对照疼痛药物治疗分析(涉及新发性环酰胺类抗抑郁药处方)。在 2150009 人年的随访期间,发生了 12123 起机动车事故(每 1000 人年 5.64 起事故)。在个体内比较中,在涉及剂量≤60 MME/天(优势比[OR],3.86;95%置信区间[CI],3.54-4.21)、>60-120 MME/天(OR,5.46;95%CI,4.44-6.73)和>120 MME/天(OR,3.45;95%CI,2.31-5.15)的阿片类药物处方期间,发生机动车事故的风险高于治疗期间。阴性对照分析支持结果的特异性是针对阿片类药物而不是针对与药物治疗相关的其他过程。这些发现表明,即使接受剂量≤60 MME/天的处方阿片类药物也与机动车事故风险增加相关。